As cardio R&D shrinks in size, a new study highlights some serious pitfalls – and a positive shift
In biotech circles, it’s become an article of faith that cancer offers some of the best prospects in new drug development. Cardiology, meanwhile, looks like a long, expensive and risky prospect. And a new study now underscores the impact that shift in attitude has had, while spotlighting a solidly upbeat migration to a new generation of therapies looking to carve out some novel results as me-too drugs are relegated to the sidelines. The authors, including Aaron Kesselheim at Brigham and Women’s, also call out developers for failing to publish the results of failed studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.